This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xiao, E. Articles by Ferin, M. Search for Related Content PubMed PubMed Citation Articles by Xiao, E. Articles by Ferin, M.

Astressin B, a Corticotropin-Releasing Hormone Receptor Antagonist, Accelerates the Return to Normal Luteal Function after an Inflammatory-Like Stress Challenge in the Rhesus Monkey

Department of Obstetrics and Gynecology (E.X., L.X.-Z., N.V., M.F.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; and The Salk Institute (J.R.), La Jolla, California 92186

Address all correspondence and requests for reprints to: Michel Ferin, Department of Obstetrics and Gynecology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032. E-mail: mf8{at}columbia.edu.

Endogenous release of CRH in stress has been associated with a dysfunctional reproductive endocrine axis. In the rhesus monkey, an inflammatory-like stress challenge in the luteal phase decreases luteal secretory function. Here, we tested the effectiveness of astressin B, a nonspecific CRH receptor antagonist, in constraining the deleterious impact of a 10-d lipopolysaccharide (LPS) challenge on the menstrual cycle. Two protocols were carried out in nine animals. In the first, the animals, after showing two normal consecutive control cycles, were injected daily for 10 days with LPS (75–125 µg/d) during the luteal phase of the cycle. The animals were followed through the two postchallenge cycles. The second protocol, carried out in the following year, was identical with protocol 1, except that the animals were treated with astressin B (0.45 mg/kg) 1 h before each daily LPS challenge during the luteal phase. Blood samples were obtained daily to document cyclic hormones levels. The LPS challenge significantly decreased luteal progesterone and LH release during the challenge cycle. Inhibition of luteal progesterone extended to the two successive postchallenge cycles. Astressin B treatment prevented luteal LH but not luteal progesterone decrease during the treatment cycle and restored normal progesterone secretion during the two posttreatment cycles. We conclude that the deleterious impact of a short-term inflammatory stress challenge on luteal function is far longer than the stress period itself. Systemic administration of astressin B accelerates the return to normal luteal function, presumably by restoring normal neuroendocrine regulation of gonadotropin secretion.

This article has been cited by other articles:

				C. L. Rivier Urocortin 1 Inhibits Rat Leydig Cell Function Endocrinology, December 1, 2008; 149(12): 6425 - 6432. [Abstract] [Full Text] [PDF]

				N. R Vulliemoz, E. Xiao, L. Xia-Zhang, J. Rivier, and M. Ferin Astressin B, a Nonselective Corticotropin-Releasing Hormone Receptor Antagonist, Prevents the Inhibitory Effect of Ghrelin on Luteinizing Hormone Pulse Frequency in the Ovariectomized Rhesus Monkey Endocrinology, March 1, 2008; 149(3): 869 - 874. [Abstract] [Full Text] [PDF]

				X. F. Li, J. S. Kinsey-Jones, A. M. I. Knox, X. Q. Wu, D. Tahsinsoy, S. D. Brain, S. L. Lightman, and K. T. O'Byrne Neonatal Lipopolysaccharide Exposure Exacerbates Stress-Induced Suppression of Luteinizing Hormone Pulse Frequency in Adulthood Endocrinology, December 1, 2007; 148(12): 5984 - 5990. [Abstract] [Full Text] [PDF]